IBIO Stock Risk & Deep Value Analysis
iBio Inc
Healthcare β’ Biotechnology
DVR Score
out of 10
What You Need to Know About IBIO Stock
We analyzed iBio Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran IBIO through our deep value framework β analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is IBIO Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
High
Competitive Risk
High
Execution Risk
High
Regulatory Risk
Medium
What Are the Red Flags for IBIO?
- β
Negative or inconclusive Phase 1 clinical trial results
- β
Further equity dilution to fund operations
- β
Failure to secure additional funding or partnerships
- β
Competitive advancements in plant-based expression or target indications
Unlock IBIO Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does iBio Inc (IBIO) Do?
Market Cap
$40.13M
Sector
Healthcare
Industry
Biotechnology
Employees
20
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and MUC16 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2Βexpressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Visit iBio Inc WebsiteIs IBIO Stock Undervalued?
Unlock the full AI analysis for IBIO
Get the complete DVR score, risk analysis, and more
Does IBIO Have a Competitive Moat?
Sign in to unlockMoat Rating
βͺ None
Moat Trend
Stable
Moat Sources
1 Identified
The FastPharming technology represents a potential competitive advantage, but its durability as a true moat is unproven. It depends heavily on successful clinical validation, demonstrating clear advantages over traditional mammalian cell culture or microbial systems, and securing robust patent protection that withstands challenges. Without successful commercialization and differentiation, it remains a promising technology rather than a durable moat.
Moat Erosion Risks
- β’Failure of lead therapeutic candidates in clinical trials
- β’Emergence of superior or more cost-effective expression systems by competitors
- β’Challenges in scaling up manufacturing to commercial levels for human therapeutics
- β’Patent challenges or expiry eroding IP protection
IBIO Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive IBIO Stock Higher?
Near-Term (0-6 months)
- β’Q1 2026 Earnings Report (estimated late April 2026)
- β’Preclinical data updates for lead candidates (IBIO-101, IBIO-200 series)
Medium-Term (6-18 months)
- β’Initial Phase 1 clinical trial data readout for lead oncology candidate (IBIO-101)
- β’Potential strategic partnership or collaboration announcement for FastPharming platform or specific programs
Long-Term (18+ months)
- β’Advancement of lead candidates into Phase 2 clinical trials
- β’Broader adoption and validation of FastPharming technology across multiple therapeutic areas
- β’Successful commercialization of a novel plant-based therapeutic
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for IBIO?
- β
Positive Phase 1 clinical trial data for IBIO-101 (efficacy, safety, tolerability)
- β
New strategic partnerships or significant non-dilutive funding rounds
- β
Reduction in quarterly cash burn without compromising R&D
Bull Case Analysis
See what could go right with Premium
π Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer β Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for IBIO (iBio Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
